MNOK 50 subscribed in Lytix Biopharma

Oslo Cancer Cluster member Lytix Biopharma AS has completed a successful issue that was subscribed shares of over 50 million NOK. It was signed for in total 71,670 shares at a subscription price of NOK 700 per share. The company will, after the capital increase is registered in the ‘Business Register’, have 207 shareholders. CEO […]

Horizon 2020: Major possibilities

Horizon 2020 is the new European Framework Program for Research and Innovation. Oslo Cancer Cluster encourage our members to take a closer look at the possibilities Horizon 2020 represents for funding R&D oncology projects and also taking part in international networks. Norwegian participation in the EU framework programs has been of critical importance to Norwegian […]

Inven2 strike major deal

Inven2 grants exclusive worldwide license to its epidermal growth factor receptor (EGFR) inhibitors patent portfolio to Merck. Researchers and clinicians at Sørlandet Hospital have discovered that the EGFR inhibitors may play a vital role as a pain reliever for so called neuropathic pain. This is a potential novel use of the growth factor inhibitor that up until now have […]

Bayer with marketing approval in EU for Algeta-developed drug

Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo® for the treatment of prostate cancer patients with  bone metastases. The marketing authorization provides approval for the commercialization of Xofigo in all 28 countries of the EU, and in Norway, Iceland and Liechtenstein following national approval. This decision follows a positive recommendation […]

Oncoinvent, Lytix and PCI granted funding

Three Oslo Cancer Cluster SME`s emerged as the winners of the Immuno-Oncology Innovation Call. Oncoinvent was as a clear number one of the 10 applications received. For the first time Oslo Cancer Cluster had the opportunity to grant funding to collaborative innovation projects under the NCE Program’s “Innovasjonsrammen”. Oncoinvent, Lytix Biopharma and PCI Biotech submitted […]

Norwegian Cancer Society grant MNOK 160

The 2013 year’s grant to cancer research in Norway, 160 million NOK (EUR 20 M) is the largest grant the Norwegian Cancer Society has ever given. “It is fantastic that we are able to provide such a large amount to our top cancer researchers in Norway”, says Secretary-General Anne Lise Ryel, Norwegian Cancer Society. “This […]